PRMT5 and MAP Kinase Inhibitor Combo Drives Complete Tumor Regressions in Preclinical Models

Plans for phase I trials follow preclinical results showing that pairing PRMT5 inhibitors with MAP kinase blockers eradicates tumors lacking key suppressor genes